Approval · Notice of Compliance 3289 · 1997
LIPITOR: Notice of Compliance 3289
Issued February 19, 1997
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 3289
- Date
- February 19, 1997
- Company
- Parke-Davis Division, Warner-Lambert Canada Inc.Scarborough, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Priority-NAS
- Therapeutic class
- Lipid metabolism regulator
Products in this notice
Medicinal ingredients
- ATORVASTATIN CALCIUM 10 MG per TAB
- ATORVASTATIN CALCIUM 20 MG per TAB
- ATORVASTATIN CALCIUM 40 MG per TAB